echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > EClinicalMed: A new genetic mutation site related to the outcome of hematopoietic stem cell transplantation in patients with hematological malignancies!

    EClinicalMed: A new genetic mutation site related to the outcome of hematopoietic stem cell transplantation in patients with hematological malignancies!

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The identification of non-human leukocyte antigen (HLA) genetic risk factors may improve the survival rate of patients after allogeneic blood or bone marrow transplantation (BMT) through additional site matching or individualized risk prediction
    .
    Researchers speculate that non-HLA locus variation has a significant contribution to the 1-year overall survival (OS), disease-related mortality (DRM) or transplant-related mortality (TRM) after BMT derived from unrelated donors (URD) and carry out the relevant analyzes to verify the findings recently published in the lancet on child Journal


    .


    Non-HLA locus variation has a significant contribution to the 1-year overall survival (OS), disease-related mortality (DRM) or transplant-related mortality (TRM) after BMT derived from a non-relative donor (URD) non-HLA locus Variants have a significant contribution to the 1-year overall survival (OS), disease-related mortality (DRM) or transplant-related mortality (TRM) after BMT derived from unrelated donors (URD).


    This is a study of 2887 patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL) from two independent cohorts (2000-2011 ) and their ≥8/8 Genome-wide Association Analysis ( GWAS ) performed in HLA-matched URD
    .

    2887 GWAS patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL)

    Variants associated with overall survival

    Variants associated with overall survival

    Through the meta-analysis of the two cohorts, multiple non-HLA locus variants were found in the whole genome and are closely related to the clinical outcome of patients after transplantation: overall survival (OS) and the rs9990017 locus variation on the MBNL1 gene of the recipient and LINC02774 gene rs10927108 donor site - receptor gene Related mismatches (risk 1.
    4, 95% CI 1.
    24-1.
    56 than [the HR], respectively, P = 3.
    3 × 10 -8 and 1.
    34, 95% CI 1.
    21-1.
    48 , p=2.
    0×10 -8 )
    .

    Overall survival (OS) receptor MBNL1 on gene rs9990017 site variants and LINC02774 gene rs10927108 Receptor Gene Related mismatch - donor sites overall survival (OS) receptor MBNL1 on gene rs9990017 site variation and LINC02774 gene rs10927108 donor site - receptor gene Related mismatch of MBNL1 rs9990017 LINC02774 rs10927108 -8 -8

    Variants associated with disease-related mortality

    Variants associated with disease-related mortality

    Disease-related mortality (DRM) and PCNX4 of the donor genome ( rs79076914 , HR 1.
    7, 95% CI 1.
    41–2.
    05, p=3.
    15×10 -8 ), LINC01194 ( rs79498125 , HR 1.
    86, 95% CI 1.
    49–2.
    31, p =2.
    84×10 -8 ), ARID5B( rs2167710 , HR 1.
    5, 95% CI 1.
    31--1.
    73, p=6.
    9×10 -9 ) and CT49 ( rs32250 , HR 1.
    44, 95% CI 1.
    26--1.
    64, p=2.
    6×10 -8 ) is related to the locus variation
    .

    Disease-related mortality (DRM) and the donor genome disease-related mortality (DRM) and the donor genome PCNX4 PCNX4 PCNX4 rs79076914 -8 LINC01194 LINC01194 LINC01194 rs79498125 -8 ARID5BARID5B ARID5B rs2167710 -9 CT49 CT49 CT49 rs32250 -8 on Locus variation is related
    .
    The locus variation on the related


    .


    Variants associated with transplant mortality

    Transplant-related mortality (TRM) and the rs141591562 mutation of the TRM gene in the recipient genome (HR 2.


    33, 95% CI 1.


    Transplant-related mortality (TRM) and the recipient genome TRM gene rs141591562 site variants related mortality (TRM) and the graft recipient genome TRM gene rs141591562 site variants TRM rs141591562 -8 and EPGN and MTHF2DL between gene rs75868097 site for member - receptor genotype mismatches and EPGN and MTHF2DL between gene rs75868097 site donor - acceptor genotype mismatch EPGN MTHF2DL rs75868097 -9 Related Related

    In conclusion, the results of this study prove for the first time that non-HLA common genetic variants of new gene loci with biochemical functions can also significantly affect the one-year survival rate after URD-BMT ; it provides new insights for donor selection and can guide treatment strategies And after future verification and functional research, two personalized risk predictions will be provided


    The non-HLA common genetic variation of the new gene locus with biochemical function can also significantly affect the one-year survival rate after URD-BMT The non-HLA common genetic variation of the new gene locus with biochemical function can also significantly affect the post URD-BMT One-year survival rate

    Original source:

    Original source:

    Theresa Hahn, et al.


    Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.